Company Profile

Vaxcyte Stock Price, News & Catalysts

Ticker:
PCVX
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

61.61 USD (-2.78%)

Close

Last updated: November 16, 2026

6.85B USD

Market cap

Why the stock is moving

As of Nov 16, 2026, PCVX closed down 2.78% at $61.61. No new same-company headline was identified in the current news window.

Company overview

Carrier-Sparing Vaccine Platform

Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses.

Adult VAX-31 Program

VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The OPUS program compares its immune responses with currently available pneumococcal vaccines and evaluates coadministration and safety.

Infant VAX-31 Program

A Phase 2 dose-finding study is evaluating VAX-31 as part of the primary infant immunization series and a booster dose.

VAX-A1

VAX-A1 is a preclinical vaccine designed to protect against disease caused by Group A *Streptococcus* and is preparing for initial testing in adults.

Manufacturing Infrastructure

Vaxcyte and Lonza have completed construction of dedicated large-scale manufacturing capacity intended to support future global supply of the company's pneumococcal vaccines.

Future catalysts

  • Phase 3 OPUS-2 and OPUS-3 results for adult VAX-31 in the first half of 2027.
  • Primary-series and booster data from the infant VAX-31 Phase 2 study by the end of the first half of 2027.
  • Topline Phase 1 VAX-A1 data in the second half of 2027.
  • Planned VAX-31 BLA submission in the first half of 2028.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Vaxcyte (PCVX)?

Vaxcyte (PCVX) most recently closed at 61.61 USD, a -2.78% move versus the previous session.

What is the market cap of Vaxcyte (PCVX)?

Vaxcyte currently has a market capitalization of 6.85B USD on BioPharmSignal.

What does Vaxcyte do?

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The OPUS program compares...

On which exchange is PCVX stock listed?

Vaxcyte (PCVX) is associated with NASDAQ, United States, Biopharma.

What is VAX-31?

Phase 3 OPUS-2 and OPUS-3 results for adult VAX-31 in the first half of 2027.

Which conditions is Vaxcyte targeting with VAX-31?

Phase 3 OPUS-2 and OPUS-3 results for adult VAX-31 in the first half of 2027.

How does Vaxcyte describe recent progress with VAX-31?

Phase 3 OPUS-2 and OPUS-3 results for adult VAX-31 in the first half of 2027.

What is VAX-A1?

VAX-A1 VAX-A1 is a preclinical vaccine designed to protect against disease caused by Group A *Streptococcus* and is preparing for initial testing in adults.